Investing Profile

Kush Parmar

InvestorVC

Managing Partner at 5AM Ventures

5amventures.comBoston, Massachusetts

Your Intro Paths to Kush Parmar

Signal uses Gmail to reveal intro paths. Email content is never read.

Find Kush Parmar on

Current Investing Position

5am Ventures Managing Partner

Investment Range

$100K - $5.0M

Sweet Spot

$1.5M

Investments On Record

Kush Parmar is on these Sector & Stage Rankings

BioTech (Series B)BioTech (Seed)BioTech (Series A)Boston / New England

Kush Parmar's Investments On Record (8)

Company	StageDateRound Size	Total Raised
Precede Biosciences	Series BJan 2026$64M Series AOct 2023$57M	$120M
Co-investors: Wouter Meuleman (Illumina Ventures)
ProLynx	Series ADec 2025$70M	$70M
Co-investors: Peter Thompson (OrbiMed)
Ensoma	Series UnknownSep 2025$53M Series BJan 2023$85M Series AFeb 2021$70M	$260M
Co-investors: Stephen Knight (F-Prime Capital Partners), Kouki Harasaki (M12 - Microsoft's Venture Fund)
Vor Biopharma	Series BJul 2020$110M Series AFeb 2019$42M	$210M
Co-investors: Reid Hoffman (Greylock)
Akouos	Series BMar 2020$110M Series AAug 2018$50M SeedNov 2017$8M	$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Heather Preston
Cleave Therapeutics	Series CAug 2019$12M Series BAug 2016$37M Series ANov 2011$42M	$100M
Co-investors: Carol Gallagher (New Enterprise Associates (NEA)), Robert Garland (New Enterprise Associates (NEA)), Peter Thompson (OrbiMed), Andrew Schwab (5am Ventures), Marc Singer (Osage University Partners), Larry Lasky (The Column Group), Alfred Scheidegger (Nextech Invest)
Arvinas	Series CApr 2018$55M Series BOct 2015$42M Series ASep 2013$15M	$140M
Co-investors: Tim Shannon (Canaan Partners), Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Jakob Loven (Nextech Invest), Andrew Levin (RA Capital), Martin Alexander Gershon (Endeavor Venture Funds), Daniel Wagner (Connecticut Innovations)
Audentes Therapeutics	Series COct 2015$65M Series BDec 2014$43M Series AJul 2013$30M	$140M
Co-investors: Jonathan Silverstein (OrbiMed), Stephen Squinto (OrbiMed), Tom Woiwode (Versant Ventures), Jonathan Leff (Deerfield Management)